BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//financecalendar.com - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:financecalendar.com
X-ORIGINAL-URL:https://www.financecalendar.com
X-WR-CALDESC:Events for financecalendar.com
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20280312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20281105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T160500
DTEND;TZID=America/New_York:20270202T170500
DTSTAMP:20261019T232827Z
CREATED:20261019T232827Z
LAST-MODIFIED:20261019T232827Z
UID:3010-1801584300-1801587900@www.financecalendar.com
SUMMARY:Merck (MRK) Earnings Q1 2027
DESCRIPTION:Next MRK Quarterly Earnings: Tuesday\, February 2\, 2027 at 4:05 pm ET (9:05 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\nNon-GAAP EPS -$0.13 (Q2 2026\, miss vs $0.23 est.)\nActual\nPending\n\nUpdated October 19\, 2026 \n\nMerck & Co. (NYSE: MRK)\, known as MSD outside the United States and Canada\, is expected to report its fourth-quarter and full-year 2026 financial results on Tuesday\, February 2\, 2027\, with the release and conference call scheduled for 4:05pm ET (9:05pm London). The date has not yet been confirmed by Merck and is based on the company’s usual pattern of reporting full-year results in the first days of February\, as it did on February 3\, 2026 for the 2025 fiscal year. Investors across the US\, Europe and Asia watch this release closely because Merck is one of the world’s largest pharmaceutical companies\, with its cancer drug Keytruda alone generating tens of billions of dollars a year in sales. Full schedule and background: Merck earnings calendar. \nThe event sits within Merck’s broader quarterly reporting calendar\, which also includes calls on drug approvals\, patent developments and dividend announcements throughout the year. Because the pharmaceutical sector trades on long-term pipeline expectations as much as short-term sales\, a single quarterly report rarely moves Merck’s share price as dramatically as\, say\, a central bank rate decision moves currency markets. Even so\, large misses or beats against Wall Street expectations can shift sentiment across the wider healthcare sector\, given Merck’s size and influence as a bellwether stock. \nWhat is the Merck Q4 2026 earnings release?\nThis is Merck’s quarterly results announcement\, in which the company discloses revenue\, profit (both under standard GAAP accounting rules and an adjusted “non-GAAP” measure that strips out one-off items like acquisition costs)\, and guidance for the coming year. Merck’s chief executive\, Robert M. Davis\, and chief financial officer typically host a call with analysts straight after the figures are published\, taking questions on drug sales\, pipeline progress and cost pressures such as US tariffs. Because Merck sells medicines and vaccines in more than 140 countries\, the results also offer a read on global healthcare demand and currency effects on multinational earnings. Analysts also use the call to probe management on regulatory risk\, including ongoing discussions in the US around drug pricing reform and the impact of tariffs on pharmaceutical supply chains\, both of which have featured prominently in recent Merck results releases. \nWhen is the release and how to follow it\nMerck usually issues its results via press release before the US market opens or\, for recent quarters\, in the early afternoon\, followed by a webcast conference call in the afternoon. For the comparable Q4 2025 report\, the results were published on February 3\, 2026. As this date is an estimate\, readers should check Merck’s investor relations site nearer the time for the confirmed date and webcast link. The call is typically archived on the same page for anyone who misses the live broadcast. \nShareholders and journalists based in Europe should note the late evening London time of 9:05pm\, which means the market reaction is usually first visible in US after-hours trading rather than during European trading hours. Asian markets\, including Tokyo and Hong Kong\, will typically see any reaction unfold during their following trading session. \nWhat to expect\nA consensus forecast for the Q4 2026 report has not yet been published\, as analyst estimates for quarters this far ahead are not yet widely tracked. For context\, analysts surveyed by Yahoo Finance had pencilled in full-year 2026 non-GAAP earnings per share (EPS) of around $2.66 to $2.76\, according to Merck’s own guidance issued in its second-quarter 2026 results. Investors will watch Keytruda sales growth\, progress in Merck’s vaccines business\, and the integration costs from the acquisition of Terns Pharmaceuticals\, which weighed heavily on second-quarter 2026 results. Guidance for 2027\, including any update on patent expiries and pipeline drugs intended to offset Keytruda’s eventual loss of exclusivity\, will also be closely read. \nMerck’s recent quarters have been notably volatile on a reported basis because of large one-off charges\, including costs tied to its acquisition of Terns Pharmaceuticals and earlier licensing payments to Hengrui Pharmaceutical. These items have pushed GAAP and non-GAAP EPS into negative territory in some quarters even as underlying product sales continued to grow\, a distinction investors will want to keep in mind when comparing headline numbers across quarters. \n\n\n\nQuarter\nRevenue\nNon-GAAP EPS\nvs estimate\n\n\n\n\nQ3 2025\n$17.28 billion\n$2.58\nBeat ($2.35 est.)\n\n\nQ4 2025\n$16.40 billion\n$2.04\nBeat ($2.02 est.)\n\n\nQ1 2026\nNot separately confirmed\n-$1.28\nBeat (-$1.48 est.)\n\n\nQ2 2026\n$16.61 billion\n-$0.13\nMiss ($0.23 est.)\n\n\n\nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat on EPS and revenue\, strong 2027 guidance\nShares likely rise\, reassurance for pharma sector sentiment\nMerck’s drug sales and cost control are stronger than analysts expected\, and the outlook for next year looks healthier\n\n\nIn line with estimates\nLimited share price reaction either way\nResults broadly match what analysts already priced in\, so little changes for investors\n\n\nMiss on EPS or weak 2027 guidance\nShares likely fall\, renewed focus on Keytruda patent cliff\nProfit or sales growth disappoints\, raising concerns about how Merck will replace future lost revenue from its top-selling drug\n\n\n\nWhat It Means for Your Money\nMerck is a large constituent of major US indices\, so it is held\, directly or indirectly\, in many pension funds\, workplace pension schemes and index-tracking investment funds across the UK\, Europe and Asia. A strong or weak result can move the healthcare sector of those funds even if an individual saver has never bought the stock directly. For currency markets\, Merck’s global sales mean its results can offer a small signal on dollar demand relative to the pound and euro\, though this effect is modest compared with central bank decisions. For ordinary consumers\, Merck’s drug pricing strategy and any guidance on US policy toward medicine costs can be an early indicator of trends that eventually affect prescription and insurance costs in the United States\, with less direct impact on UK and European patients who largely rely on national health systems. \nRelated events\n\nMerck’s third-quarter 2026 earnings release\, typically reported in late October\nPfizer and Johnson & Johnson quarterly earnings\, often released in the same reporting window\nUS Food and Drug Administration decisions affecting Merck’s pipeline drugs\n\nFrequently Asked Questions\nWhat time does Merck report its Q4 2026 earnings?\nThe release is expected at 4:05pm ET (9:05pm London) on February 2\, 2027\, though Merck has not yet confirmed the exact date. \nWhat was Merck’s most recent EPS?\nIn its most recently reported quarter\, Merck posted non-GAAP EPS of -$0.13\, missing the analyst estimate of $0.23\, largely due to acquisition-related charges\, according to Merck’s own results announcement. \nIs there a consensus forecast for this report yet?\nNo\, a consensus forecast has not yet been published for the Q4 2026 results\, as estimates this far ahead are not widely tracked by analysts. \nWhy does Merck’s earnings report matter beyond the US?\nMerck sells medicines and vaccines in more than 140 countries\, so its results offer a broader read on global healthcare demand\, drug pricing trends and currency effects that can ripple into pension and index funds held by investors in the UK\, Europe and Asia. \nWhere can I watch the earnings call live?\nMerck typically streams its earnings call via a webcast link posted on its investor relations website\, with a replay available afterwards.
URL:https://www.financecalendar.com/event/merck-mrk-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
END:VCALENDAR